Ind-Swift Laboratories Limited INDSWFTLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.indswiftlabs.com

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.

Market & Price

Market Cap

₹1,320.87 Cr

Current Price

₹152.11

High / Low (52W)

₹152.11 / ₹79.46

Beta

Valuation

Stock P/E

4.41

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹163.64

Price to Book

0.93

P/S

1.92

EV/EBITDA

10.35

Dividend Yield

Profitability & Returns

ROCE

21.28%

ROE

3.24%

ROA

2.47%

Profit Margin

6.02%

Op Margin

32.19%

EPS (Latest Qtr)

₹1.13

EPS (TTM)

₹34.48

Balance Sheet & Liquidity

Debt/Equity

1.48

Quick Ratio

2.49

Current Ratio

3.80

Debt

₹20.50 Cr

Total Assets

₹1,438.34 Cr

Current Assets

₹865.35 Cr

Working Capital

₹644.77 Cr

Ownership

Promoter Holding

59.52%

Chg in Prom Hold

FII / Inst Holding

4.62%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹953.28 Cr

Total Revenue (TTM)

₹688.26 Cr

EBITDA

₹92.06 Cr

Free Cash Flow

₹-113.21 Cr

Operating Cash Flow

₹-69.88 Cr

Shares Outstanding

₹8.68 Cr

Gross Margin

58.96%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-18.53%

Profit 5Y

3,918.50%

Revenue (YoY)

-54.30%

Earnings (YoY)

-95.00%

PROS

Healthy ROCE of 21.3%.
Profit CAGR of 3918.5% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -18.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INDSWFTLAB Ind-Swift Laboratories Limited NSEPHARMA	152.11	4.41	₹1,320.87 Cr	-	21.28%	3.24%	-18.53%	3,918.50%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Dec 2025
Revenue	148.30 Cr	128.80 Cr	507.92 Cr	152.64 Cr	150.85 Cr
Cost of Revenue	78.20 Cr	61.67 Cr	296.43 Cr	77.65 Cr	70.24 Cr
Gross Profit	70.10 Cr	67.13 Cr	211.50 Cr	74.99 Cr	80.61 Cr
Operating Expenses	72.78 Cr	79.59 Cr	216.36 Cr	80.50 Cr	85.27 Cr
Operating Income	-2.67 Cr	-12.46 Cr	-4.86 Cr	-5.50 Cr	-4.66 Cr
EBITDA	20.24 Cr	9.26 Cr	281.77 Cr	19.34 Cr	25.90 Cr
Interest Expense	9.94 Cr	10.03 Cr	68.89 L	2.01 Cr	67.37 L
Pretax Income	4.70 Cr	-6.58 Cr	257.32 Cr	10.34 Cr	16.39 Cr
Tax Provision	18.45 L	-1.08 Cr	8.19 Cr	2.30 Cr	6.87 Cr
Net Income	4.53 Cr	-5.49 Cr	249.12 Cr	7.99 Cr	9.54 Cr
Diluted EPS	0.67	-0.82	-	0.96	1.13

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	1,038.73 Cr	1,207.31 Cr	1,709.15 Cr	561.71 Cr
Cost of Revenue	629.12 Cr	766.86 Cr	996.71 Cr	338.27 Cr
Gross Profit	409.61 Cr	440.45 Cr	712.44 Cr	223.44 Cr
Operating Expenses	317.19 Cr	258.93 Cr	469.99 Cr	265.08 Cr
Operating Income	92.42 Cr	181.52 Cr	242.45 Cr	-41.64 Cr
EBITDA	235.02 Cr	230.28 Cr	776.43 Cr	283.66 Cr
Interest Expense	91.45 Cr	86.39 Cr	97.80 Cr	1.38 Cr
Pretax Income	12.53 Cr	86.52 Cr	598.22 Cr	257.80 Cr
Tax Provision	14.68 Cr	38.69 Cr	58.98 Cr	7.27 Cr
Net Income	-2.15 Cr	47.60 Cr	538.75 Cr	250.48 Cr
Diluted EPS	-4.28	-4.28	91.18	35.21

Compounded Sales Growth

5 Years:	-18.53%
1 Year:	-54.30%

Compounded Profit Growth

5 Years:	3,918.50%
1 Year:	-95.00%

Stock Price Performance

1 Year:	+91.43%
6 Months:	+58.91%
3 Months:	+6.92%
1 Month:	+10.59%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	1,800.79 Cr	1,824.06 Cr	1,460.43 Cr	1,438.34 Cr
Current Assets	1,075.33 Cr	1,164.52 Cr	959.46 Cr	865.35 Cr
Cash & Equivalents	21.48 Cr	18.20 Cr	477.81 Cr	412.04 Cr
Inventory	428.50 Cr	438.60 Cr	74.55 Cr	114.18 Cr
Receivables	454.78 Cr	505.32 Cr	312.97 Cr	164.52 Cr
Total Liabilities	1,199.93 Cr	1,142.13 Cr	648.37 Cr	265.37 Cr
Current Liabilities	334.47 Cr	371.09 Cr	432.97 Cr	220.58 Cr
Long Term Debt	847.78 Cr	752.60 Cr	198.74 Cr	25.71 Cr
Total Debt	953.02 Cr	862.10 Cr	216.80 Cr	40.86 Cr
Total Equity	600.97 Cr	681.93 Cr	812.08 Cr	1,173.00 Cr
Shares Outstanding	5.91 Cr	5.91 Cr	5.91 Cr	6.06 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	150.27 Cr	194.62 Cr	-186.98 Cr	-25.47 Cr
Investing Cash Flow	4.77 Cr	-13.37 Cr	-27.15 Cr	-109.62 Cr
Financing Cash Flow	-140.88 Cr	-185.66 Cr	657.35 Cr	69.20 Cr
Capital Expenditure	-18.41 Cr	-12.77 Cr	-73.01 Cr	-64.41 Cr
Free Cash Flow	131.86 Cr	181.85 Cr	-259.99 Cr	-89.88 Cr
Net Change in Cash	14.17 Cr	-4.41 Cr	443.22 Cr	-65.89 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	39.4%	36.5%	41.7%	39.8%
Operating Margin %	8.9%	15.0%	14.2%	-7.4%
Net Margin %	-0.2%	3.9%	31.5%	44.6%
ROE %	-0.4%	7.0%	66.3%	21.4%
ROCE %	6.3%	12.5%	23.6%	-3.4%

Shareholding Pattern

Insiders

59.52%

Institutions

4.62%

Public Float

11.42%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDSWFTLAB

No recent headlines available.

INDSWFTLAB · Healthcare